Search | Clinical Trials Finder

Conditions: HIV-1
Interventions: D/C/F/TAF FDC placebo; Drug
Lead sponsor: Janssen Pharmaceutica N.V., Belgium; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Phoenix, Arizona • Atlanta, Georgia • Memphis, Tennessee + 1 more

Conditions: Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions: abacavir/lamivudine, abacavir, lamivudine, tenofovir; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 30
States / cities: Los Angeles, California • Oakland, California • Fort Lauderdale, Florida + 20 more

Conditions: HIV Infections
Interventions: Abacavir sulfate; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: Evanston, Illinois • Boston, Massachusetts • Albany, New York

Conditions: HIV-1 Infection
Interventions: depo-medroxyprogesterone acetate; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 13 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 13
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 7 more

Conditions: HIV-1-infection
Interventions: lepetegravir, lenacapavir pacfosacil, Bictegravir/emtricitabine/tenofovir alafenamide, lepetegravir/lenacapavir pacfosacil FDC, Placebo to Match BVY, Placebo to Match GS1720/GS-4182 FDC; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 21
States / cities: Birmingham, Alabama • Torrance, California • West Hollywood, California + 17 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more

Conditions: HIV
Interventions: Switch to Maraviroc + Raltegravir or Dolutegravir; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: Profectus HIV MAG pDNA vaccine, IL-12, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 13
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 8 more

Conditions: HIV
Interventions: Atazanavir, Darunavir, Ritonavir, Optimized NRTI backbone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 14
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 8 more

Conditions: Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions: No intervention; Observational study; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 13 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 6
States / cities: Fort Lauderdale, Florida • Orlando, Florida • Tampa, Florida + 2 more

Conditions: HIV Infections
Interventions: Abacavir sulfate, Lamivudine, Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 13
States / cities: Berkeley, California • Los Angeles, California • Washington D.C., District of Columbia + 9 more

Conditions: HIV Infection, Monoclonal Antibody, Human, HIV Antibodies, VRC01 Monoclonal Antibody, Neutralizing Antibody
Interventions: VRC-HIVMAB060-00-AB; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Abacavir sulfate, Amprenavir, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: VCR-HIVDNA006-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1997
U.S. locations: 6
States / cities: Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more

Conditions: HIV Infections
Interventions: ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1999
U.S. locations: 6
States / cities: Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more

Conditions: HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 3 Months
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 45
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 29 more

Conditions: HIV Infections
Interventions: Nevirapine XR, Nevirapine IR; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 11
States / cities: Beverly Hills, California • Long Beach, California • Los Angeles, California + 6 more

Conditions: HIV Infections
Interventions: CD4-IgG; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 5 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 7
States / cities: San Diego, California • Miami, Florida • Chicago, Illinois + 4 more

Conditions: HIV-1-infection, Metabolic Syndrome
Interventions: physical activity; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: HIV Infections
Interventions: Prednisone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Honolulu, Hawaii + 9 more

Conditions: HIV Infections
Interventions: VRC-HIVDNA-016-00-VP, VRCHIVADV014-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV-1-infection
Interventions: Rapid start of antiretrovirals, Retrospective analysis, Non- RAPID start; Behavioral
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: HIV Infections
Interventions: HIV-MAG vaccine, IL-12 pDNA adjuvant, VSV HIV gag vaccine, Placebo, Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device; Biological · Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 5
States / cities: New York, New York • Rochester, New York • Philadelphia, Pennsylvania + 1 more

Search by objective public record fields.

Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

A Study of 1592U89 in HIV-Infected Patients

Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women

Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated

A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC

Switch to Maraviroc + Integrase Inhibitor

Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)

The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs

Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults

Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients

HIV-1 Vaccine Test in Uninfected Adult Volunteers

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers

A Study of Didanosine Use Alone or in Combination With Zidovudine in Infants Exposed to or Infected With HIV

Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection

Healthy Lifestyles: A Home Based Physical Activity Intervention in Persons Living With HIV

The Effects of Prednisone on HIV Levels and the Immune System

Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals

Impact of Rapid ART Initiation on Retention in Care in the Southern US

Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults